Decreased expression of CD63 tetraspanin protein predicts elevated malignant potential in human esophageal cancer

Lai,Xiaojing; Gu,Qing; Zhou,Xia; Feng,Wei; Lin,Xiao; He,Yan; Cao,Jinming; Liu,Pengfei; Zhang,Huojun; Zheng,Xiao

doi:10.3892/ol.2017.6023

Decreased expression of CD63 tetraspanin protein predicts elevated malignant potential in human esophageal cancer

Authors:
- Xiaojing Lai
- Qing Gu
- Xia Zhou
- Wei Feng
- Xiao Lin
- Yan He
- Jinming Cao
- Pengfei Liu
- Huojun Zhang
- Xiao Zheng
View Affiliations

Affiliations: Department of Radiation Oncology, Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), Zhejiang Cancer Hospital (Zhejiang Cancer Research Institute), Hangzhou, Zhejiang 310022, P.R. China, School of Radiation Medicine and Protection and Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University, Soochow, Suzhou 215123, P.R. China, Department of Gastroenterology, The Affiliated Jiangyin Hospital of Southeast University, Jiangyin, Jiangsu 214400, P.R. China, Department of Radiation Oncology, Shanghai Changhai Hospital, The Second Military Medical University, Shanghai 200433, P.R. China
Published online on: April 11, 2017 https://doi.org/10.3892/ol.2017.6023
Pages: 4245-4251
Copyright: © Lai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The tetraspanin CD63 has been described to have critical roles in multiple biological processes, including tumorigenesis and metastasis in several types of cancer. However, its role in esophageal carcinoma (EC) has not been reported. In the current study, immunohistochemistry was used to investigate CD63 expression in 106 esophageal cancer samples, 49 adjacent esophagus tissues and 17 normal esophagus mucosa tissues. The results revealed that the overexpression of CD63 was observed in esophageal cancer samples and negatively correlated with tumor stage and lymph node metastasis. To further evaluate the role of CD63 in esophageal carcinoma, the invasiveness of EC cells was analyzed using matrigel invasion assays and wound healing assays in vitro. Furthermore, it was found that CD63 knockdown increased the invasiveness of TE‑1 cells through the upregulation of matrix metalloproteinase (MMP) expression via promoting epithelial‑mesenchymal transition. The current data therefore suggested that low levels of CD63 expression may be involved in the tumor progression of esophageal carcinoma.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013. View Article : Google Scholar : PubMed/NCBI
3	Dipetrillo T, Suntharalingam M, Ng T, Fontaine J, Horiba N, Oldenburg N, Perez K, Birnbaum A, Battafarano R, Burrows W and Safran H: Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: A phase 2 trial. Am J Clin Oncol. 35:64–67. 2012. View Article : Google Scholar : PubMed/NCBI
4	van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
5	Eloubeidi MA, Desmond R, Arguedas MR, Reed CE and Wilcox CM: Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: The importance of tumor length and lymph node status. Cancer. 95:1434–1443. 2002. View Article : Google Scholar : PubMed/NCBI
6	Cho JW, Choi SC, Jang JY, Shin SK, Choi KD, Lee JH, Kim SG, Sung JK, Jeon SW, Choi IJ, et al: Lymph node metastases in esophageal carcinoma: An Endoscopist's view. Clin Endosc. 47:523–529. 2014. View Article : Google Scholar : PubMed/NCBI
7	Maecker HT, Todd SC and Levy S: The tetraspanin superfamily: Molecular facilitators. FASEB J. 11:428–442. 1997.PubMed/NCBI
8	Hunziker W and Geuze HJ: Intracellular trafficking of lysosomal membrane proteins. Bioessays. 18:379–389. 1996. View Article : Google Scholar : PubMed/NCBI
9	Atkinson B, Ernst CS, Ghrist BF, Herlyn M, Blaszczyk M, Ross AH, Herlyn D, Steplewski Z and Koprowski H: Identification of melanoma-associated antigens using fixed tissue screening of antibodies. Cancer Res. 44:2577–2581. 1984.PubMed/NCBI
10	Hemler ME: Tetraspanin proteins mediate cellular penetration, invasion and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 19:397–422. 2003. View Article : Google Scholar : PubMed/NCBI
11	Hemler ME, Mannion BA and Berditchevski F: Association of TM4SF proteins with integrins: Relevance to cancer. Biochim Biophys Acta. 1287:67–71. 1996.PubMed/NCBI
12	Hölters S, Anacker J, Jansen L, Beer-Grondke K, Dürst M and Rubio I: Tetraspanin 1 promotes invasiveness of cervical cancer cells. Int J Oncol. 43:503–512. 2013.PubMed/NCBI
13	Kwon MS, Shin SH, Yim SH, Lee KY, Kang HM, Kim TM and Chung YJ: CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung. Lung Cancer. 57:46–53. 2007. View Article : Google Scholar : PubMed/NCBI
14	Kondoh M, Ueda M, Ichihashi M and Mishima Y: Decreased expression of human melanoma-associated antigen ME491 along the progression of melanoma pre-canceroses to invasive and metastatic melanomas. Melanoma Res. 3:241–245. 1993.PubMed/NCBI
15	Radford KJ, Mallesch J and Hersey P: Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491). Int J Cancer. 62:631–635. 1995. View Article : Google Scholar : PubMed/NCBI
16	Sordat I, Decraene C, Silvestre T, Petermann O, Auffray C, Piétu G and Sordat B: Complementary DNA arrays identify CD63 tetraspanin and alpha3 integrin chain as differentially expressed in low and high metastatic human colon carcinoma cells. Lab Invest. 82:1715–1724. 2002. View Article : Google Scholar : PubMed/NCBI
17	Seubert B, Cui H, Simonavicius N, Honert K, Schäfer S, Reuning U, Heikenwalder M, Mari B and Kruger A: Tetraspanin CD63 acts as a pro-metastatic factor via β-catenin stabilization. Int J Cancer. 136:2304–2315. 2015. View Article : Google Scholar : PubMed/NCBI
18	Kwon MS, Shin SH, Yim SH, Lee KY, Kang HM, Kim TM and Chung YJ: CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung. Lung Cancer. 57:46–53. 2007. View Article : Google Scholar : PubMed/NCBI
19	Jang HI and Lee H: A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cells. Exp Mol Med. 35:317–323. 2003. View Article : Google Scholar : PubMed/NCBI
20	Toricelli M, Melo FH, Peres GB, Silva DC and Jasiulionis MG: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Mol Cancer. 12:222013. View Article : Google Scholar : PubMed/NCBI
21	Zhou Z, Ran YL, Hu H, Pan J, Li ZF, Chen LZ, Sun LC, Peng L, Zhao XL, Yu L, et al: TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression. Clin Exp Metastasis. 25:537–548. 2008. View Article : Google Scholar : PubMed/NCBI
22	Kong KL, Kwong DL, Fu L, Chan TH, Chen L, Liu H, Li Y, Zhu YH, Bi J, Qin YR, et al: Characterization of a candidate tumor suppressor gene uroplakin 1A in esophageal squamous cell carcinoma. Cancer Res. 70:8832–8841. 2010. View Article : Google Scholar : PubMed/NCBI
23	Yamasaki M, Miyata H, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M and Doki Y: Evaluation of the nodal status in the 7th edition of the UICC-TNM classification for esophageal squamous cell carcinoma: Proposed modifications for improved survival stratification: Impact of lymph node metastases on overall survival after esophagectomy. Ann Surg Oncol. 21:2850–2856. 2014. View Article : Google Scholar : PubMed/NCBI
24	D'Amico TA: Outcomes after surgery for esophageal cancer. Gastrointest Cancer Res. 1:188–196. 2007.PubMed/NCBI
25	Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
26	Hotta H, Ross AH, Huebner K, Isobe M, Wendeborn S, Chao MV, Ricciardi RP, Tsujimoto Y, Croce CM and Koprowski H: Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res. 48:2955–2962. 1988.PubMed/NCBI
27	Lin D, Kamsteeg EJ, Zhang Y, Jin Y, Sterling H, Yue P, Roos M, Duffield A, Spencer J, Caplan M and Wang WH: Expression of tetraspan protein CD63 activates protein-tyrosine kinase (PTK) and enhances the PTK-induced inhibition of ROMK channels. J Biol Chem. 283:7674–7681. 2008. View Article : Google Scholar : PubMed/NCBI
28	Yoshida T, Ebina H and Koyanagi Y: N-linked glycan-dependent interaction of CD63 with CXCR4 at the Golgi apparatus induces downregulation of CXCR4. Microbiol Immunol. 53:629–635. 2009. View Article : Google Scholar : PubMed/NCBI
29	Sauer G, Kurzeder C, Grundmann R, Kreienberg R, Zeillinger R and Deissler H: Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. Oncol Rep. 10:405–410. 2003.PubMed/NCBI
30	Radford KJ, Thorne RF and Hersey P: Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line. J Immunol. 158:3353–3358. 1997.PubMed/NCBI
31	Jung KK, Liu XW, Chirco R, Fridman R and Kim HR: Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J. 25:3934–3942. 2006. View Article : Google Scholar : PubMed/NCBI
32	Tominaga N, Hagiwara K, Kosaka N, Honma K, Nakagama H and Ochiya T: RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy. Mol Cancer. 13:1342014. View Article : Google Scholar : PubMed/NCBI
33	Takino T, Miyamori H, Kawaguchi N, Uekita T, Seiki M and Sato H: Tetraspanin CD63 promotes targeting and lysosomal proteolysis of membrane-type 1 matrix metalloproteinase. Biochem Biophys Res Commun. 304:160–166. 2003. View Article : Google Scholar : PubMed/NCBI
34	Rubinstein E, Le Naour F, Lagaudrière-Gesbert C, Billard M, Conjeaud H and Boucheix C: CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Eur J Immunol. 26:2657–2665. 1996. View Article : Google Scholar : PubMed/NCBI
35	Berditchevski F, Zutter MM and Hemler ME: Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins). Mol Biol Cell. 7:193–207. 1996. View Article : Google Scholar : PubMed/NCBI
36	Berditchevski F, Bazzoni G and Hemler ME: Specific association of CD63 with the VLA-3 and VLA-6 integrins. J Biol Chem. 270:17784–17790. 1995. View Article : Google Scholar : PubMed/NCBI
37	Skubitz KM, Campbell KD, Iida J and Skubitz AP: CD63 associates with tyrosine kinase activity and CD11/CD18 and transmits an activation signal in neutrophils. J Immunol. 157:3617–3626. 1996.PubMed/NCBI
38	Radford KJ, Thorne RF and Hersey P: CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta 1 integrins in human melanoma. Biochem Biophys Res Commun. 222:13–18. 1996. View Article : Google Scholar : PubMed/NCBI
39	Si Z and Hersey P: Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma. Int J Cancer. 54:37–43. 1993. View Article : Google Scholar : PubMed/NCBI
40	Zucker S and Vacirca J: Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 23:101–117. 2004. View Article : Google Scholar : PubMed/NCBI
41	Tania M, Khan MA and Fu J: Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 35:7335–7342. 2014. View Article : Google Scholar : PubMed/NCBI